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Background: Psychosocial stress leads to altered neuroendocrine functions, such as serotonergic dysfunction, as well
as alterations of the autonomic nervous system and the hypothalamic-pituitary-adrenal (HPA)-axis activity resulting in
an imbalance between inhibitory and excitatory neurotransmitters. Poor dietary intake of L-tryptophan as a precursor
of serotonin increases sensitivity to stress.
Methods: This randomized, double-blind, placebo-controlled study investigated the effect of a specific amino acid
composition with micronutrients on neurovegetative disorders and the cardiometabolic risk profile in psychosocially
stressed patients. 32 patients (18–65 years) were eligible for protocol analysis. Points in the Psychological Neurological
Questionnaire (PNF), clinical and blood parameter, in particular the serotonin level, salivary cortisol levels, and dietary
intake were evaluated at baseline and 12 weeks after supplementation.
Results: The intervention in the form of either verum or placebo resulted in both groups in a significant decrease of
neurovegetative symptoms. However, patients of the placebo group achieved significantly less points in the PNF
compared to the verum group. But the rate of responders (≥10 points loss in PNF) was not significantly different
between the groups. The macronutrient intake did not differ between verum and placebo group. On average, the
HPA-axis was not disturbed in both groups. Blood serotonin indicated in both groups no significant correlation with
dietary tryptophan intake or PNF.
Conclusions: Daily supplementation of a specific amino acid composition with micronutrients in psychologically
stressed patients resulted in no improvement of neurovegetative disorders as measured by the PNF when compared
to the placebo group.
Trial registration: Clinical Trials.gov (NCT01425983)
Keywords: Psychosocial stress, Hypothalamus-Pituitary-Adrenal (HPA)-axis, Sympathetic nervous system (SN), Amino
acid composition, Dietary supplement, Psychological Neurological Questionnaire (PNF)Background
According to the WHO, psychosocial stress is one of the
important health risks of the century; resulting cardio-
metabolic consequences are enormous [1,2]. Affected
persons are usually characterized by neurovegetative dis-
orders as well as metabolic risk factors [1]. Quality of life
is reduced by health impairments [2].* Correspondence: christine.metzner@rwth-aachen.de
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unless otherwise stated.Physical or psychological stress leads to an increased se-
cretion of corticotropin-releasing hormone (CRH), which
affects two important stress systems: the sympathoadrenal
medullary system acts by the hormones epinephrine and
norepinephrine on cardiovascular functions, thereby in-
creasing resting heart rate and blood pressure; the enabled
hypothalamus-pituitary-adrenal (HPA)-axis goes along
with a cortisol secretion [3,4]. Somatic effects of increased
cortisol level are mainly displayed in inhibiting immune
and inflammatory responses, visceral adipose tissue, re-
duced insulin sensitivity and rising plasma glucose level
[5,6]. Dysfunction of both systems can affect the circadianral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to a certain stress factor [3], as well as a long-term in-
crease in resting heart rate and blood pressure by hyper-
activity of sympathoadrenal medullary system.
The elevated activity of serotonergic neurons in stress
diminishes during psychological stress and is associated
with mood disorders and depressive symptoms [7]. This
is followed by a growing imbalance between the excita-
tory (norepinephrine, dopamine, glutamate) and inhibi-
tory neurotransmitters (serotonin, gamma-amino-butyric
acid [GABA], glycine, taurine). Delivery of amino acids,
as precursor of neurotransmitters, within dietary supple-
ments, is an important therapeutic approach and a key
feature in nutritional therapy.
The essential amino acid L-tryptophan is the least avail-
able amino acid in human nutrition and a precursor of
serotonin. In particular, a high protein supply constitutes
also the large neutral amino acids (LNAA), which com-
pete with L-tryptophan for the blood brain barrier trans-
porter [8-10]. Central serotonin depletion increases
aggressive behaviour and stress-reactivity [11], while poor
dietary intake of L-tryptophan also increases sensitivity to
stress [12,13]. Therefore, an adequate supply with L-
tryptophan during psychological stress is necessary [14].Figure 1 Trial profile.The same applies to taurine as an inhibitory neurotrans-
mitter and ornithine, which stimulates the release of so-
matotropin, another lacking factor during stress [15].
The effects of micronutrients on mood, mild psychi-
atric symptoms and stress were discussed in a recently
published meta-analysis [16]. The authors concluded
that the recommendations for dietary intake should be
reviewed while considering these results. In particular B
vitamins [17], and few minerals as iron, selenium, mag-
nesium and zinc are mostly analysed. As an important
stress-mineral in the central nervous system [18,19], a
hypomagnesemia during stress leads to a pathogenic vi-
cious circle [20].
The aim of this study is to investigate, if daily oral ad-
ministration of an amino acid mixture in combination
with micronutrients, specifically designed to decrease
neurovegetative disorders, will target these neuroendo-




Psychologically stressed women (n = 21) and men (n = 13)
with cardiological disorders were recruited from a
Table 1 Composition of dietary intervention products
average values per daily drink (8.9 g powder/0.2 l water)
Verum Placebo
Energy 110.8 kJ/26.9 kcal 146 kJ/34.3 kcal
Protein 3.8 g >0.0 g
Carbohydrates 0.7 g 7.9 g
Fat >0.0 g >0.0 g
Amino acids
L-ornithine 2000 mg -
Taurine 1000 mg -
L-tryptophan 800 mg -
Vitamins
Vitamin C 300 mg -
Vitamin B6 25 mg -
Vitamin B2 25 mg -
Vitamin B1 25 mg -
Niacin 100 mg -
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chological stress was defined by neurovegetative disorders
determined by a standardized Psychological Neurological
Questionnaire (PNF) [21]. Patients aged between 18 and
65 years were included into the study if they obtained
30–50 points in PNF and a resting heart rate ≥ 70/min,
considering the antihypertensive drugs. Exclusion criteria
were supplementation with dietary supplements or drugs
which contain amino acids, vitamins or other micronutri-
ents, therapy with antipsychotic drugs such as tranquilizer
or antidepressants, psychological-neurological or psychi-
atric therapy and acute and chronic diarrhea. The trial pro-
file of the 80 screened participants is shown in Figure 1.
During 12 weeks of the prospective, controlled, double-
blind trial, participants were required to take one serving
of supplement (8.9 g powder; shown in Table 1) per day
solved in 200 ml of water. They got a detailed instruction
for consumption of the drink, two hours after the last
meal (between 8–10 pm). Compliance was verified by pill
counting at week four, eight and twelve.Pantothenic acid 100 mg -
Folic acid 800 μg -
Vitamin B12 50 μg -
Minerals
Magnesium 300 mg -
Zinc 15 mg -
Selenium 100 μg -
Chrome 50 μg -
Molybdenum 50 μg -Psychological neurological questionnaire
Participants answered the PNF at baseline and after
12 weeks of dietary intervention. A borderline range of
psychological stress was classified as 30–50 points,
assessed at inclusion and baseline. Responders were de-
fined by reaching a loss of 10 points or more from base-
line to week 12. The questionnaire comprises a total of
38 items which are divided into five categories of neuro-
vegetative disorders (psychoneurovegetative stability,
neurological symptoms, impulsion, arousal, concentra-
tion). The self-reported symptoms were assessed as total
points, as well as for individual categories, ranging from
“not at all” (0 points) to “often” (3 points).Clinical and laboratory methods
Prior to dietary intervention and after 12 weeks saliva
and blood samples, clinical and biochemical data were
collected. After a 10 min resting period, blood pressure
and resting heart rate were measured under standardized
conditions. The average of three simultaneous measure-
ments was determined. Anthropometric data and venous
blood samples were obtained after an overnight fasting
period of at least 12 h.
Laboratory Schottdorf MVZ GmbH, Augsburg, Germany,
conducted all laboratory analyses (see Additional file 1).
Participants got a detailed instruction for gaining
saliva-cortisol samples in the evening (2 hours after last
meal, between 8–10 pm) and morning (30 min after
awakening) at baseline and week 12. Therefore, Salivette®
sterile cotton swabs were chewed for nearly 1 min until
saturation and deposited in collection tubes, subsequently
stored in a refrigerator. Measurements were performed byusing microtiter plate reader Sunrise (Tecan, Crailsheim,
Germany) and Cortisol ELISA (IBL, Hamburg, Germany).
Three-day food records were reviewed with each par-
ticipant at baseline and week 12, the average of 3 days
was assessed. PRODI 5.5 software (WVG, Stuttgart,
Germany) with database BLS II.3 was used for the
analysis.Statistical analysis
Statistical comparisons were made between groups using
nonparametric Mann–Whitney-U test, nonparametric
Wilcoxon test was used for data comparison at different
time points within groups. Differences in classified vari-
ables were tested by Chi2 test. All statistical tests were
based on per protocol population and two-sided. Differ-
ences were considered significant at p < 0.05. Data are
reported as mean ± standard deviation (SD). All analyses
were conducted using SPSS® for Windows (version 22.0).
The study was approved by the Freiburg Ethics Com-
mission International and was registered with the U.S.
National Institutes of Health Clinical Trials.gov
(NCT01425983).
Table 2 Baseline characteristics of psychologically stressed patients in the verum and the placebo group
Verum (n = 18) Placebo (n = 16) V vs. P
x ± SD x ± SD p-value
sex (n) f 10 (56%) 11 (69%) 0.429a
m 8 (44%) 5 (31%)
Age (years) 50 ± 9 50 ± 12 0.670b
Height (cm) 172 ± 8 169 ± 10 0.313b
Weight (kg) 83 ± 17 82 ± 19 0.772b
BMI (kg/m2) 28.0 ± 4.4 28.3 ± 4.8 0.986b
≤24.5 kg/m2 5 (28%) 3 (19%) 0.825a
24.6-29.9 kg/m2 8 (44%) 8 (50%)
≥30 kg/m2 5 (28%) 5 (31%)
WC female (cm) 88 ± 11 83 ± 11 0.197b
WC f≥ 88 cm (n) 7 (70%) 3 (27%) 0.050a
WC male (cm) 100 ± 11 102 ± 17 0.524b
WC m≥ 102 cm (n) 4 (50%) 3 (60%) 0.725a
BP systolic (mmHg) 135 ± 10 131 ± 13 0.175b
≥130 mmHgci 14 (78%) 6 (38%) 0.017a
BP diastolic (mmHg) 85 ± 10 83 ± 8 0.463b
≥85 mmHg 9 (50%) 8 (50%) 1.000a
Pulse pressure 51 ± 9 48 ± 10 0.313b
rHR (1/min) 69 ± 10 73 ± 10 0.597b
PNF (points) 41 ± 5 39 ± 6 0.229b
PN (points) 16 ± 3 16 ± 4 0.873b
Impulsion (points) 8 ± 2 7 ± 2 0.215b
Concentration (points) 7 ± 3 7 ± 3 0.901b
Cortisol_m (ng/ml)c 7.5 ± 4.4 6.1 ± 3.3 0.552b
Cortisol_e (ng/ml)c 1.2 ± 1.5 1.2 ± 1.2 0.711b
ΔCortisol (ng/ml)c 6.3 ± 5.0 5.0 ± 3.8 0.652b
Serotonin (μg/l)c 180 ± 84 180 ± 47 0.444b
CRP sensitive (mg/l) 2.9 ± 3.1 6.6 ± 7.9 0.202b
GGT (U/l) 45 ± 48 21 ± 11 0.046b
TC (mg/dl) 219 ± 36 217 ± 43 0.772b
HDL-C (mg/dl) 59.0 ± 26.8 61.4 ± 18.0 0.356b
LDL-C (mg/dl) 133 ± 34 132 ± 42 0.932b
LDL-C/HDL-C 2.6 ± 1.0 2.3 ± 0.9 0.330b
TG (mg/dl) 162 ± 88 145 ± 57 0.851b
TG/HDL-C 3.4 ± 2.6 2.8 ± 1.8 0.621b
FPG (mg/dl) 99 ± 28 97 ± 16 0.798b
HbA1c (%) 5.8 ± 0.9 5.7 ± 0.3 0.330
b
HOMA-Index 3.2 ± 3.3 2.0 ± 1.2 0.330b
Insulin-ECLIA (μU/ml) 11.9 ± 8.1 8.1 ± 4.1 0.266b
abbreviations used: BP, blood pressure; BMI, body mass index; Cortisol: _m, morning; _e, evening; ΔCortisol, cortisol difference morning-evening; CRP sensitive,
C-reactive protein sensitive; ECLIA, Enhanced Chemiluminescent Immunoassay; FPG, fasting plasma glucose; GGT, gamma-glutamyltransferase; HbA1c, glycated
haemoglobin A1c; HDL-C, HDL cholesterol; HOMA-Index, Homeostasis Model Assessment-Index; LDL-C, LDL cholesterol; PNF, Psychological Neurological;
Questionnaire; PN, psycho-neurovegetative stability; rHR, resting Heart rate; TC, total cholesterol; TG, triglycerides; WC, waist circumference.p-value: aChi2 test;
bMann–Whitney-U test; c data not available for all patients (numbers listed in Additional file 2).
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Table 3 Changing of patient’s characteristics: comparison of values before and after dietary intervention
Verum (n = 18) Placebo (n = 14) V vs. P
x ± SD x ± SD week 12
Baseline Week 12a Diff Baseline Week 12a Diff pb
Weight (kg) 83.4 ± 16.5 84.5 ± 17.1* 1.1 ± 1.7 81.7 ± 19.9 82.2 ± 19.5 0.4 ± 1.2 0.722
BMI (kg/m2) 28.0 ± 4.4 28.4 ± 4.6* 0.4 ± 0.5 28.8 ± 4.9 29.0 ± 4.7 0.2 ± 0.4 0.750
WC (cm) f 88 ± 11 89 ± 11 1 ± 2 83 ± 11 84 ± 12 1 ± 2 0.218
Female≥ 88 cm (%n)+ 7 (70%) 7 (70%) 0 2 (20%) 4 (40%) 2 0.123
WC (cm) m 100 ± 11 101 ± 11 1 ± 2 109 ± 11 108 ± 12 −1 ± 1 0.368
Male≥ 102 cm (%n)+ 4 (50%) 4 (50%) 0 3 (75%) 4 (100%) 1 0.279
BP systolic (mmHg) 135 ± 10 133 ± 13 −2 ± 11 130 ± 14 132 ± 17 2 ± 12 0.955
≥130 mmHg (%n) 14 (78%) 10 (56%) −4 5 (36%) 10 (71%) 5 0.681
BP diastolic (mmHg) 85 ± 10 85 ± 9 0 ± 8 83 ± 8 84 ± 10 0 ± 10 0.512
Pulse pressure 51 ± 9 50 ± 7 −1 ± 11 46 ± 10 49 ± 11 3 ± 8 0.357
rHr (1/min) 69 ± 10 72 ± 9 3 ± 6 73 ± 10 72 ± 12 −1 ± 9 0.808
PNF 41 ± 5 33 ± 8* −8 ± 9 39 ± 6 22 ± 9* −17 ± 12 0.003
PN 16 ± 3 12 ± 4* −3 ± 3 16 ± 3 10 ± 5* −7 ± 5 0.168
Cortisol_m (ng/ml)c 7.5 ± 4.4 6.6 ± 4.1 −0.5 ± 3.6 6.0 ± 3.4 5.3 ± 3.4 −0.7 ± 3.4 0.425
Cortisol_e (ng/ml)c 1.2 ± 1.5 1.5 ± 1.6 0.6 ± 1.7 1.2 ± 1.2 0.9 ± 0.9 −0.3 ± 0.8 0.533
ΔCortisol (ng/ml)c 6.3 ± 5.0 5.6 ± 4.8 −0.6 ± 4.1 4.8 ± 3.9 4.4 ± 3.5 −0.4 ± 3.5 0.454
Serotonin (μg/l)c 171 ± 90 185 ± 100 5 ± 34 180 ± 50 190 ± 64 11 ± 30 0.356
CRP sensitive (mg/l) 2.9 ± 3.1 2.4 ± 2.6 −0.7 ± 2.9 7.1 ± 8.0 6.0 ± 7.8 −1.0 ± 2.5 0.120
GGT (U/l) 45 ± 48 58 ± 71* 13 ± 25 23 ± 11 24 ± 14 1.6 ± 4.8 0.180
TC (mg/dl) 219 ± 36 211 ± 40 −8 ± 22 217 ± 43 216 ± 36 −1 ± 20 0.561
HDL-C (mg/dl) 59 ± 27 59 ± 26 0 ± 6 62 ± 19 61 ± 14 −0.8 ± 9.3 0.301
LDL-C (mg/dl) 133 ± 34 125 ± 36 −8 ± 19 132 ± 44 132 ± 32 0 ± 21 0.561
LDL-C/HDL-C 2.6 ± 1.0 10.1 ± 32.9 −0.4 ± 0.8 2.3 ± 0.9 2.3 ± 1.0 0 ± 0.5 0.561
TG (mg/dl) 162 ± 88 153 ± 87 −9 ± 39 145 ± 61 136 ± 39 −10 ± 42 0.808
TG/HDL-C 3.4 ± 2.6 6.0 ± 11.9 2.6 ± 11.6 2.9 ± 2.0 2.5 ± 1.2 −0.4 ± 1.1 0.536
FPG (mg/dl) 99 ± 28 102 ± 44 3 ± 17 97 ± 17 92 ± 10 −5 ± 18 0.891
HbA1c (%) 5.8 ± 0.9 5.8 ± 0.9 0.1 ± 0,2 5.7 ± 0.3 5.7 ± 0.3 0 ± 0.3 0.750
HOMA-Index 3.2 ± 3.3 3.6 ± 3.7 0.4 ± 2.6 2.2 ± 1.2 2.5 ± 1.9 0.3 ± 1.8 0.488
Insulin-ECLIA (μU/ml) 11.9 ± 8.1 2.3 ± 1.0 −1.3 ± 6.1 8.8 ± 4.0 10.5 ± 7.5 1.8 ± 6.5 0.955
abbreviations used: BP, blood pressure; BMI, body mass index; Cortisol: _m, morning; _e, evening; ΔCortisol, cortisol difference morning-evening; CRP sensitive,
C-reactive protein sensitive; Diff, difference; ECLIA, Enhanced Chemiluminescent Immunoassay; FPG, fasting plasma glucose; GGT, gamma-glutamyltransferase;
HbA1c, glycated haemoglobin A1c; HDL-C, HDL cholesterol; HOMA-Index, Homeostasis Model Assessment-Index; LDL-C, LDL cholesterol; PNF, Psychological
Neurological Questionnaire; PN, psycho-neurovegetative stability; rHR, resting heart rate; TC, total cholesterol; TG, triglycerides; WC, waist circumference.
p-value: aWilcoxon-test within groups, bMann–Whitney-U test: *p < 0.05.
cdata not available for all patients (numbers listed in Additional file 2).
+Verum: women n = 10, men n = 8; Placebo: women n = 10, men n = 4.
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Patient’s characteristics
A total of 34 patients were randomized into verum and
placebo groups, 32 patients were left for protocol analysis
(Figure 1). Two patients of the placebo group discontin-
ued the study as early dropouts, both for personal reasons.
Daily servings were well tolerated by the majority of pa-
tients, one patient of the verum group got a cholecystitis
during intervention, two patients of each group indicatedgastrointestinal complaints or nausea in the morning.
There was no correlation to supplementation assumed.
The patient’s characteristics at baseline are shown in
Table 2. The difference of GGT was mainly caused by
extreme values in the verum group. About three quar-
ters of patients were overweight. Systolic blood pressure
indicated an increased activity of sympathoadrenal sys-
tem in both groups. But only at inclusion, most patients
of verum group met the criteria of elevated resting heart
Table 4 Dietary intake before and after intervention
Verum (n = 18) x ± SD Placebo (n = 14) x ± SD V vs. P week 12
Baseline Week 12a Baseline Week 12a pb
Energy (kcal) 2627 ± 694 2427 ± 556 2453 ± 625 2601 ± 937 0.779
Carbohydrates (g) 280 ± 88 260 ± 77 248 ± 72 275 ± 114 0.543
Protein (g) 103 ± 23 97 ± 28 101 ± 25 106 ± 33 0.470
Fat (g) 114 ± 40 97 ± 25 107 ± 42 107 ± 41 0.879
SFA (g) 43.1 ± 12.3 37.5 ± 14.0 41.4 ± 15.9 38.0 ± 9.4 0.543
MUFA (g) 41.2 ± 19.5 39.7 ± 19.3 35.7 ± 18.1 35.2 ± 10.8 0.909
PUFA (g) 18.8 ± 9.6 18.3 ± 8.9 15.5 ± 7.5 15.8 ± 5.9 0.543
n-6 FA (g) 16.4 ± 9.1 15.9 ± 8.3 12.7 ± 6.6 13.8 ± 5.7 0.569
n-3 FA (g) 2.0 ± 1.1 2.1 ± 0.9 2.5 ± 2.2 1.7 ± 0.8 0.166
abbreviations used: MUFA, monounsaturated fatty acids; n-3 FA, omega-3 fatty acids; n-6 FA, omega-6 fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated
fatty acids.
p-value: aWilcoxon-test within groups, bMann–Whitney-U test.
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tions, to state an activated sympathoadrenal system. A
significant influence on patients with antihypertensive
drugs had been excluded.
Additionally, the HPA-axis was not disturbed as shown
by saliva cortisol measurement and a serotonin defi-
ciency was not detectable in the blood (Table 2 and
Additional file 2). Blood serotonin indicated in both
groups no significant correlation with dietary tryptophan
intake or PNF. Thus, this initial situation was not as ex-
pected and complicated the data interpretation.
Psychological neurological questionnaire
After 12 weeks of supplementation, patients of both groups
indicated a significant improvement of neurovegetative dis-
orders. Patients of the placebo group achieved significantly
less points in the PNF compared to the verum group
(Table 3 and Additional file 2). However, the rate of re-
sponders (≥10 points loss in PNF) was not significantly
different between verum (n = 7) and placebo group (n = 9;
p = 0.154).
Nutritional impact
Absolute values of energy- and macronutrient-intake did
not significantly differ between verum and placebo
group (Table 4). Overall, the unfavourable fat-intake
based on a poor ratio of n-6 fatty acids/n-3 fatty acids
(n-6 FA/n-3 FA) and a large share of saturated fatty
acids (SFA). Even after taking the supplements, there
was no evidence of a significant change in protein-, fat-
or SFA-intake (Table 4).
Discussion
The present study investigated whether daily supplementa-
tion of an amino acid mixture with micronutrients specific-
ally decreases neurovegetative disorders in psychologicallystressed adults as compared to a placebo. After 12-week
dietary intervention both groups demonstrated a signifi-
cant reduction of characteristic symptoms. Surprisingly the
patients of the placebo group reported significantly less
points than the patients of verum group.
The PNF could be discussed as a tool for establishing
chronic stress [22]. Here, we used a borderline range of
psychological stress for determining chronically stressed
patients. In order to detect the verum’s effectiveness,
pre-post intervention changes in total number of points
were analysed, as well as the rate of responder. Consid-
ering the results presented here, it seems to be some-
what difficult to distinguish between a placebo effect
and the actual efficacy. Two-thirds of the placebo group
presented a significantly greater decrease in total points
than in the verum group. This placebo effect cannot be
explained out of the baseline-situation in comparison to
the verum group.
The assumptions of a disturbed HPA-axis and a sero-
tonin deficiency were not met for most patients. There-
fore, the diagnosis of psychological stress was merely
confirmed by the PNF and in a diminished manner by
elevated resting heart rate. Although another clinical
study showed that there seemed to be no correlations of
blood serotonin and central serotonin in humans [23].
Considering these results, in following studies the blood
concentration of amino acids and micronutrients would
be even better parameter to control an improvement, es-
pecially the relation of available tryptophan to the
remaining LNAA [24].
Many unpredictable effects such as changes in nutri-
tional behaviour over time, which are difficult to control
for, bias results even in carefully designed studies [25].
The nutritional effect of carbohydrates and protein on
mood has been discussed for some time [26-28]. A high-
fat diet is supposed to have a protective effect on
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be assumed that the composition of consumed food af-
fected mood, behaviour and neurovegetative disorders in
the psychologically stressed patients of our study.
Although there were no significant differences in nu-
tritional intake between the groups, the SFA-intake was
remarkable. Other authors stated that the impact of a
self-medication by eating palatable foods during chronic
stress, leads to a high-fat diet in these patients, thereby
protecting against stress-induced effects [30,31]. It has
also been shown in rodents that a high-fat diet protects
against the effects of chronic stress exposure [32,33] while
the animals on a low-fat diet reacted with weight gain and
increased caloric intake [32]. Psychologically stressed pa-
tients often respond with weight gain and an unconscious
change of their eating behaviour [34,35]. These changes
couldn’t be observed in this study population.
Although considering the protective effects of a high-fat
diet in short-term, the increased fat-intake will become
habitual [36,37] and thus will lead to a deterioration of the
cardiometabolic situation in long-term [38,39]. The after-
effects of a long-lasting high-fat diet were shown in ro-
dents and include increasing levels of insulin, insulin
resistance and mild hyperglycemia [24,32,40,41].
As a study limitation, there would be to mention the
small sample size, which decreases the statistical power,
in particular for the comparison of subgroups but also
for the detection of marginal changes. The low participa-
tion could be attributed to the impacts of chronic stress
and should be recognized as a non-participation bias.
Concurrently, the selection of participants was locally
limited, and most of them were handicapped by cardio-
logical therapy, although significant impairment by anti-
hypertensive drugs was excluded.
The connection between a high-fat diet and chronic
stress exposure is widely examined in studies with ro-
dents [29,33]. In this pilot study, we showed that these
correlations could also exist in psychologically stressed
humans and therefore, provided some clues for further
investigations in a larger cohort.Conclusions
Daily supplementation of a specific amino acid composition
with micronutrients in psychologically stressed patients
resulted in no improvement of neurovegetative disorders as
measured by the PNF when compared to the placebo
group.Additional files
Additional file 1: Laboratory analyses.
Additional file 2: Valid numbers for cortisol and serotonin values.
Considering Tables 2 and 3: cdata not available for all patients. Missingcortisol values due to material deficiency for measuring. Missing
serotonin values due to value below limit of detection (<16 μg/l).
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